Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies
- PMID: 28479851
- PMCID: PMC5411168
- DOI: 10.2147/DDDT.S130568
Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies
Abstract
Background: Recent studies have suggested a potential increased risk of acute kidney injury (AKI) among proton-pump inhibitor (PPI) users. However, the present results are conflicting. Thus, we performed a meta-analysis to investigate the association between PPI therapy and the risk of AKI.
Methods: EMBASE, PubMed, Web of Science, and Cochrane Library databases (up to September 23, 2016) were systematically searched for any studies assessing the relationship between PPI use and risk of AKI. Studies that reported relevant risk ratios (RRs), odds ratios, or hazard ratios were included. We calculated the pooled RRs with 95% confidence intervals (CI) using a random-effects model of the meta-analysis. Subgroup analysis was conducted to explore the source of heterogeneity.
Results: Seven observational studies (five cohort studies and two case-control studies) were identified and included, and a total of 513,696 cases of PPI use among 2,404,236 participants were included in the meta-analysis. The pooled adjusted RR of AKI in patients with PPIs use was 1.61 (95% CI: 1.16-2.22; I2=98.1%). Furthermore, higher risks of AKI were found in the subgroups of cohort studies, participant's average age <60 years, participants with and without baseline PPI excluded, sample size <300,000, and number of adjustments ≥11. Subgroup analyses revealed that participants with or without baseline PPI excluded might be a source of heterogeneity.
Conclusion: PPI use could be a risk factor for AKI and should be administered carefully. Nevertheless, some confounding factors might impact the outcomes. More well-designed prospective studies are needed to clarify the association.
Keywords: acute kidney injury; meta-analysis; proton-pump inhibitor; risk.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures


Similar articles
-
The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.Nephrol Dial Transplant. 2018 Feb 1;33(2):331-342. doi: 10.1093/ndt/gfw470. Nephrol Dial Transplant. 2018. PMID: 28339835
-
Association of Proton Pump Inhibitor Use and Immune Checkpoint Inhibitor-Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes.Am J Nephrol. 2024;55(4):439-449. doi: 10.1159/000538274. Epub 2024 Mar 12. Am J Nephrol. 2024. PMID: 38471492 Free PMC article.
-
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.Pharmacotherapy. 2019 Apr;39(4):443-453. doi: 10.1002/phar.2235. Epub 2019 Mar 21. Pharmacotherapy. 2019. PMID: 30779194 Free PMC article.
-
Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury.Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1155-72. doi: 10.1002/pds.3329. Epub 2012 Aug 9. Pharmacoepidemiol Drug Saf. 2012. PMID: 22887960
-
Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.Kidney Int. 2017 Jun;91(6):1482-1494. doi: 10.1016/j.kint.2016.12.021. Epub 2017 Feb 22. Kidney Int. 2017. PMID: 28237709
Cited by
-
The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events.Drugs. 2019 May;79(7):715-731. doi: 10.1007/s40265-019-01110-3. Drugs. 2019. PMID: 30972661 Review.
-
Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.J Gastroenterol. 2023 Apr;58(4):358-366. doi: 10.1007/s00535-023-01966-z. Epub 2023 Feb 13. J Gastroenterol. 2023. PMID: 36781490 Clinical Trial.
-
Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis.Biomedicines. 2024 Jun 25;12(7):1414. doi: 10.3390/biomedicines12071414. Biomedicines. 2024. PMID: 39061988 Free PMC article. Review.
-
The relationship between proton pump inhibitors and renal disease.J Bras Nefrol. 2018 Jul-Sep;40(3):301-306. doi: 10.1590/2175-8239-jbn-2018-0021. Epub 2018 Jul 10. J Bras Nefrol. 2018. PMID: 30010692 Free PMC article. Review.
-
Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.Pharmacol Res Perspect. 2020 Oct;8(5):e00651. doi: 10.1002/prp2.651. Pharmacol Res Perspect. 2020. PMID: 32996701 Free PMC article.
References
-
- Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–2754. - PubMed
-
- Grace Newsome E, American College of Rheumatology Guidelines for the management of rheumatoid arthritis: 2002 update. J Am Acad Nurse Pract. 2002;14(10):432–437. - PubMed
-
- Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008;68(7):925–947. - PubMed
-
- Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources